L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C Bio Co. Ltd (290650) - Total Liabilities
Latest total liabilities as of September 2025: ₩231.24 Billion KRW
Based on the latest financial reports, L&C Bio Co. Ltd (290650) has total liabilities worth ₩231.24 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
L&C Bio Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
L&C Bio Co. Ltd Competitors by Total Liabilities
The table below lists competitors of L&C Bio Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Coship Electronics Co Ltd
SHE:002052
|
China | CN¥373.66 Million |
|
Kingsignal Technology Co Ltd
SHE:300252
|
China | CN¥2.85 Billion |
|
Sanyang Motor Co Ltd
TW:2206
|
Taiwan | NT$54.58 Billion |
|
NCR Voyix Corporation
NYSE:VYX
|
USA | $2.88 Billion |
|
Piedmont Office Realty Trust Inc
NYSE:PDM
|
USA | $2.53 Billion |
|
Hapag-Lloyd Aktiengesellschaft
PINK:HLAGF
|
USA | $11.41 Billion |
|
Charoen Pokphand Enterprise Taiwan Co Ltd
TW:1215
|
Taiwan | NT$18.78 Billion |
|
Qisda Corp
TW:2352
|
Taiwan | NT$142.09 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down L&C Bio Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how L&C Bio Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for L&C Bio Co. Ltd (2015–2024)
The table below shows the annual total liabilities of L&C Bio Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩191.25 Billion | +65.89% |
| 2023-12-31 | ₩115.29 Billion | +13.28% |
| 2022-12-31 | ₩101.77 Billion | +354.74% |
| 2021-12-31 | ₩22.38 Billion | -1.71% |
| 2020-12-31 | ₩22.77 Billion | +183.10% |
| 2019-12-31 | ₩8.04 Billion | +63.60% |
| 2018-12-31 | ₩4.92 Billion | +33.68% |
| 2017-12-31 | ₩3.68 Billion | -34.81% |
| 2016-12-31 | ₩5.64 Billion | +8.52% |
| 2015-12-31 | ₩5.20 Billion | -- |